Author

K. S. Yang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 6 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:drug response / drug discovery· 5 Organism:human· 3 Organism:virus· 2 Organism:E. coli· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1

Frequent Co-Authors

S. Xu· 7 shared W. R. Liu· 7 shared E. C. Vatansever· 4 shared Y. R. Alugubelli· 4 shared L. R. Blankenship· 3 shared X. R. Ma· 3 shared Y. J. Sheng· 3 shared Y. Ma· 3 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersBiochemistry

S. Xu

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease

Z. Z. Geng, S. Atla, N. Shaabani, V. R. Vulupara, K. S. Yang, Y. R. Alugubelli, K. Khatua, P.-H. C. Chen, J. Xiao, L. R. Blankenship, X. R. Ma, E. C. Vatansever, C.-C. Cho, Y. Ma, R. Allen, , W. R. Liu

This study systematically evaluates dipeptidyl inhibitors of SARS-CoV-2 main protease, identifying compounds with high antiviral potency and low cytotoxicity.

bioRxiv · Jan 17, 2023Biochemistry

Phage-Assisted, Active Site-Directed Ligand Evolution of a Potent and Selective Histone Deacetylase 8 Inhibitor

J. S. Morse, Y. J. Sheng, J. T. Hampton, L. D. Sylvain, S. Das, Y. R. Alugubelli, P.-H. C. Chen, K. S. Yang, S. Xu, C. A. Fierke, W. R. Liu

This paper develops PADLE, a phage-assisted method to evolve potent HDAC8 inhibitors, identifying two highly selective and potent inhibitors with sub-nanomolar Ki values.

bioRxiv · Sep 14, 2022Biochemistry

A Novel Y-Shaped, S-O-N-O-S-Bridged Crosslink between Three Residues C22, C44, and K61 Is a Redox Switch of the SARS-CoV-2 Main Protease

K. S. Yang, S.-T. A. Kuo, L. R. Blankenship, Y. J. Sheng, B. Sankaran, P. Li, C. A. Fierkee, D. H. Russell, X. Yan, S. Xu, W. R. Liu

The paper identifies a novel Y-shaped crosslink in SARS-CoV-2 MPro that acts as a redox switch, regulating its catalytic activity and offering new targets for antiviral drug development.

bioRxiv · Apr 29, 2022 · PreprintBiochemistry

Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics

W. Cao, C.-C. D. Cho, Z. Z. Geng, X. R. Ma, R. Allen, N. Shaabani, E. C. Vatansever, Y. R. Alugubelli, Y. Ma, W. H. Ellenburg, K. S. Yang, Y. Qiao, H. Ji, S. Xu, W. R. Liu

This paper evaluates the cellular potency of SARS-CoV-2 MPro inhibitors using a fluorescent flow cytometry assay, revealing that most inhibitors have weak cellular activity despite strong antiviral effects.

bioRxiv · Jun 8, 2021 · PreprintBiochemistry

Drug Repurposing for the SARS-CoV-2 Papain-Like Protease

C.-C. D. Cho, S. G. Li, K. S. Yang, T. J. Lalonde, G. Yu, Y. Qiao, S. Xu, W. R. Liu

This study screens inhibitors against SARS-CoV-2 PLpro, identifying several potent compounds with IC50 values below 60 μM, including SJB2-043 with an IC50 of 0.56 μM.

bioRxiv · Jun 4, 2021Biochemistry

A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors

W. R. Liu, K. S. Yang, X. R. Ma, Y. Ma, Y. R. Alugubelli, D. A. Scott, E. C. Vatansever, A. K. Drelich, Z. Z. Geng, L. R. Blankenship, B. Sankaran, H. E. Ward, Y. J. Sheng, J. C. Hsu, K. K. Kratch, , H. S. Hayatshahi

This study designs and synthesizes potent SARS-CoV-2 main protease inhibitors, with some showing IC50 values below 100 nM and high virus inhibition potency in cell assays.

bioRxiv · Jul 28, 2020 · PreprintBiochemistry

Bepridil is Potent Against SARS-CoV-2 In Vitro

E. C. Vatansever, K. S. Yang, K. C. Kratch, A. Drelich, C.-C. Cho, D. M. Mellott, S. Xu, C.-T. K. Tseng, W. R. Liu

This study identifies bepridil as a potent inhibitor of SARS-CoV-2 MPro and virus entry, showing efficacy in vitro at low concentrations.

bioRxiv · May 23, 2020Pharmacology & Toxicology